WomenEarly Phase 1NCT07674680
Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women
A Early Phase 1 study testing Gemtesa in people with Women and Aging, run by University of Missouri-Columbia at 1 site in United States.
Trial summary
To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women. Read more about this study
- Who is it for?
- Ages 18 to 70 years, women onlyHealthy volunteers can take part
- What is being tested?
- Gemtesa
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Jul 2026to May 2029
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy women,
- Assigned female at birth,
- 18-70 years of age,
- Body mass index <18 or ≥30 kg/m2,
Who cannot join
- Assigned male at birth,
- Pregnancy,
- Breastfeeding,
- History of hormone replacement therapy, chemical menopause, or oophor-ectomy
- Polycystic ovarian syndrome or Primary ovarian insufficiency,
- Current smoking/Nicotine use,
Show all 13Show fewer
- Blood pressure ≥140/90 mmHg,
- Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy,
- Nerve/neurologic disease,
- Cardiovascular, hepatic, renal, respiratory disease,
- Hypersensitivity to nitroglycerin,
- Diabetes,
- Communication barriers,
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Missouri
Columbia, Missouri, 65211
Jacqueline Limberg Associate Professor, 1-573-882-2544, limberglab@missouri.edu
About this study
To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.
- Being tested
- Placebo, Gemtesa
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Participants will receive a placebo in pill form.
GemtesaDrug
Participants will receive oral gemtesa (75 mg).
| Study group | Role | What they receive |
|---|---|---|
| Cold pressor test | Experimental | Participants will be exposed to the cold pressor test (ice water on the foot). Receives: Drug: Placebo; Drug: Gemtesa |
| Flow Mediated Dilation | Experimental | Participants will be exposed to the high-resolution ultrasound following inflation of a cuff around the forearm. Receives: Drug: Placebo; Drug: Gemtesa |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood flow
Blood flow measured with Doppler ultrasound.
Measured: Change from baseline to minute 2.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2026
- Study start31 Jul 2026
- Primary completionMay 2028 (estimated)
- Study completionMay 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for WomenStudies of the same condition, open and under way.
- More trials run by University of Missouri-ColumbiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Missouri-Columbia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jacqueline K Limberg, PhD, University of Missouri-Columbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07674680
- Sponsor's protocol ID
- 2135088
- Status last verified
- Sep 2026
- First submitted
- 17 Jun 2026
- Last updated
- 10 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women
- ClinicalTrials.gov ID
- NCT07674680
- Acronym / sponsor ID
- 2135088
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University of Missouri-ColumbiaUniversity, hospital or other
- Study start
- 31 Jul 2026 (actual)
- Primary completion
- May 2028 (estimated)
- Study completion
- May 2029 (estimated)
- First posted
- 29 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cold pressor test | Experimental | Drug: Placebo, Drug: GemtesaParticipants will be exposed to the cold pressor test (ice water on the foot). |
| Flow Mediated Dilation | Experimental | Drug: Placebo, Drug: GemtesaParticipants will be exposed to the high-resolution ultrasound following inflation of a cuff around the forearm. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Healthy women,
- Assigned female at birth,
- 18-70 years of age,
- Body mass index <18 or ≥30 kg/m2,
Key exclusion criteria (13 listed)
- Assigned male at birth,
- Pregnancy,
- Breastfeeding,
- History of hormone replacement therapy, chemical menopause, or oophor-ectomy
- Polycystic ovarian syndrome or Primary ovarian insufficiency,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboParticipants will receive a placebo in pill form. | Drug | Cold pressor test, Flow Mediated Dilation |
| GemtesaParticipants will receive oral gemtesa (75 mg). | Drug | Cold pressor test, Flow Mediated Dilation |
Primary outcome
Blood flow
Time frame: Change from baseline to minute 2.
Blood flow measured with Doppler ultrasound.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Women
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Gemtesa in people with Women and Aging, run by University of Missouri-Columbia at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jacqueline Limberg Associate Professor (1-573-882-2544, limberglab@missouri.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood flow (time frame: Change from baseline to minute 2.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.